Objective
To examine the incidence of first diagnosis of invasive squamous cell carcinoma (SCC) of the skin over time.
Design
Retrospective, population-based incidence study.
Setting
Enumerated, geographically isolated, semiurban population served by the Mayo Clinic and its affiliated hospitals and the Olmsted Medical Center, including its affiliated hospital in Rochester, Minn.
Methods
Using the Rochester Epidemiology Project databases that capture virtually all medical care provided to the residents of Rochester, we identified and reviewed records of all documented residents in whom histologically proven, invasive SCC of the skin was first diagnosed between 1984 and 1992. Age and sex stratum-specific rates were calculated, and age-adjusted rates observed over time for individuals aged 35 years or older were analyzed using Poisson regression. Adjusted rates were compared with the results of other studies.
Results
Review of 1630 records identified 511 incidence cases of SCC. Tumors located on the head and neck accounted for 66.4% of tumors in females and 72.9% in males. The annual age- and sex-specific incidence rates per 100 000 increased from 0 cases among males aged 0 to 14 years to 1286.0 cases among males aged 85 years or older. Over time, the annual age-adjusted incidence rates per 100 000 females rose from 46.5 (95% confidence interval [CI], 32.4-60.6) for the 1984 to 1986 period to 99.6 (95% CI, 80.4-118.7) for the 1990 to 1992 period and were 71.2 (95% CI, 61.7-80.8) overall. The corresponding rates for males were 125.9 (95% CI, 95.3-156.4), 191.0 (95% CI, 156.9-225.0), and 155.5 (95% CI, 137.0-174.0). The age- and sex-adjusted SCC incidence rates for the period from 1987 to 1989 and 1990 to 1992 exceeded those for the period from 1984 to 1986 (P=.03 and P<.001, respectively). Our age-adjusted rates for SCC were within the ranges seen in other white populations from temperate climates.
Conclusion
The frequencies of first diagnosis of SCC are increasing at rates beyond those explainable by demographic shifts alone.
Arch Dermatol. 1997;133:735-740
Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases
Burmester et al.
Ann Rheum Dis 2009;68:1863-1869.
ABSTRACT
| FULL TEXT
Long-term Safety and Efficacy of 50 mg of Etanercept Twice Weekly in Patients With Psoriasis
Tyring et al.
Arch Dermatol 2007;143:719-726.
ABSTRACT
| FULL TEXT
Incidence of Basal Cell and Squamous Cell Carcinomas in a Population Younger Than 40 Years
Christenson et al.
JAMA 2005;294:681-690.
ABSTRACT
| FULL TEXT
No Evidence for Increased Risk of Cutaneous Squamous Cell Carcinoma in Patients With Rheumatoid Arthritis Receiving Etanercept for Up to 5 Years
Lebwohl et al.
Arch Dermatol 2005;141:861-864.
ABSTRACT
| FULL TEXT
Nonmelanoma Skin Cancer in Survivors of Childhood and Adolescent Cancer: A Report From the Childhood Cancer Survivor Study
Perkins et al.
JCO 2005;23:3733-3741.
ABSTRACT
| FULL TEXT
Mortality Risk From Squamous Cell Skin Cancer
Clayman et al.
JCO 2005;23:759-765.
ABSTRACT
| FULL TEXT
Sentinel Node Biopsy for High-Risk Nonmelanoma Cutaneous Malignancy
Wagner et al.
Arch Dermatol 2004;140:75-79.
ABSTRACT
| FULL TEXT
Changes in Nonmelanoma Skin Cancer Incidence between 1977-1978 and 1998-1999 in Northcentral New Mexico
Athas et al.
Cancer Epidemiol. Biomarkers Prev. 2003;12:1105-1108.
ABSTRACT
| FULL TEXT
Time Trends and Familial Risks in Squamous Cell Carcinoma of the Skin
Hemminki et al.
Arch Dermatol 2003;139:885-889.
ABSTRACT
| FULL TEXT
Cutaneous Squamous-Cell Carcinoma
Alam and Ratner
NEJM 2001;344:975-983.
FULL TEXT
